ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Mycosis Fungoides, Non-Hodgkin's Lymphoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, Argentina, Australia, Brazil, China +2
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Overview
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Primary outcome measures
- Overall survival (OS) [Time frame: date of diagnosis to death from any cause, up to two years]
Eligibility criteria
Inclusion criteria
- Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
- Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available
Exclusion criteria
- Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
- Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
- Exclude one-time consultation type of new patients.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 7 centers
- City of Hope — Duarte
- Stanford University, School of Medicine — Palo Alto
- University of Iowa — Iowa City
- Hackensack University Medical Center — Hackensack
- University of Pittsburg — Pittsburgh
- University of Texas Southwestern — Dallas
- University of Utah Hospital — Salt Lake City
Argentina · 1 center
- Hospital Italiano de Buenos Aires — Buenos Aires
Australia · 1 center
- Peter MacCallum Cancer Center, — Melbourne
Brazil · 1 center
- University of Sao Paulo Medical School — São Paulo
China · 1 center
- Peking University First Hospital — Beijing
Japan · 1 center
- The University of Tokyo — Tokyo
United Kingdom · 1 center
- University Hospitals Birmingham — Birmingham
Publications
- Scarisbrick JJ, Quaglino P, Whittaker S, Bagot M, Guenova E, Papadavid E, Prince HM, Sanches JA, Miyashiro DR, Servitje O, Querfeld C, Akilov O, Arumainathan A, Bennett L, Battistella M, Benstead K, Berti E, Beylot-Barry M, Busschots AM, Cowan R, Dummer R, Dunnill G, Estrach T, Evison F, Bashir A, Geskin L, Gru A, Guitart J, Herrera MC, Hodak E, Horwitz S, Jonak C, Klemke CD, Knobler R, Mckay P, M PMID 40663780
Identifiers
NCT: NCT02848274 · IRB-32652 · LYMNHL0134 · NCI-2020-00940